Evidence map›Paper›PMID 38706981›Full record

ArticleNature machine intelligence2023

Federated benchmarking of medical artificial intelligence with MedPerf.

Alexandros Karargyris, Renato Umeton, Micah J Sheller, Alejandro Aristizabal, Johnu George, Anna Wuest, Sarthak Pati, Hasan Kassem, Maximilian Zenk, Ujjwal Baid and 67 more

Abstract read
In one paragraph

Article in Nature machine intelligence, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Adaptable Segmentation Pipeline for Diverse Brain Tumors with Radiomic-guided Subtyping and Lesion-Wise Model Ensemble.Segmentation, classification, and synthesis for brain tumors and traumatic brain injuries : MICCAI 2025 Challenges: BraTS-Lighthouse 2025 and AIMS-TBI 2025, held in conjunction with MICCAI 2025, Daejeon, South Korea, September 23, 2025,... · 2026
    Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

77 authors.

Alexandros KarargyrisIHU Strasbourg, Strasbourg, France.ORCID 0000-0002-1930-3410
Renato UmetonDana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-5561-6932
Micah J ShellerIntel, Santa Clara, CA, USA.ORCID 0000-0002-6571-0850
Alejandro AristizabalFactored, Palo Alto, CA, USA.
Johnu GeorgeNutanix, San Jose, CA, USA.
Anna WuestDana-Farber Cancer Institute, Boston, MA, USA.
Sarthak PatiPerelman School of Medicine, Philadelphia, PA, USA.ORCID 0000-0003-2243-8487
Hasan KassemUniversity of Strasbourg, Strasbourg, France.ORCID 0000-0001-5830-8890
Maximilian ZenkGerman Cancer Research Center, Heidelberg, Germany.ORCID 0000-0002-8933-5995
Ujjwal BaidPerelman School of Medicine, Philadelphia, PA, USA.
Prakash Narayana MoorthyIntel, Santa Clara, CA, USA.
Alexander ChowdhuryDana-Farber Cancer Institute, Boston, MA, USA.
Junyi GuoHarvard T.H. Chan School of Public Health, Boston, MA, USA.
Sahil NalawadeDana-Farber Cancer Institute, Boston, MA, USA.
Jacob RosenthalDana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-1767-1826
David KanterMLCommons, San Francisco, CA, USA.
Maria XenochristouStanford University, Stanford, CA, USA.
Daniel J BeutelUniversity of Cambridge, Cambridge, UK.
Verena ChungSage Bionetworks, Seattle, WA, USA.
Timothy BergquistSage Bionetworks, Seattle, WA, USA.ORCID 0000-0001-5614-8977
James EddySage Bionetworks, Seattle, WA, USA.
Abubakar AbidHugging Face, New York, NY, USA.
Lewis TunstallHugging Face, New York, NY, USA.
Omar SansevieroHugging Face, New York, NY, USA.
Dimitrios DimitriadisMicrosoft, Redmond, WA, USA.
Yiming QianA*STAR, Singapore, Singapore.ORCID 0000-0002-1795-2038
Xinxing XuA*STAR, Singapore, Singapore.ORCID 0000-0003-1449-3072
Yong LiuA*STAR, Singapore, Singapore.
Rick Siow Mong GohA*STAR, Singapore, Singapore.
Srini BalaSupermicro, San Jose, CA, USA.
Victor BittorfMeta, Menlo Park, CA, USA.
Sreekar Reddy PuchalaDana-Farber Cancer Institute, Boston, MA, USA.
Biagio RicciutiDana-Farber Cancer Institute, Boston, MA, USA.
Soujanya SamineniDana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-1056-8006
Eshna SenguptaDana-Farber Cancer Institute, Boston, MA, USA.
Akshay ChaudhariStanford University, Stanford, CA, USA.ORCID 0000-0002-3667-6796
Cody ColemanStanford University, Stanford, CA, USA.
Bala DesinghuRutgers University, New Brunswick, NJ, USA.
Gregory DiamosLanding.AI, Palo Alto, CA, USA.
Debo DuttaNutanix, San Jose, CA, USA.
Diane FeddemaRed Hat, Raleigh, NC, USA.
Grigori FursincKnowledge, Paris, France.ORCID 0000-0001-7719-1624
Xinyuan HuangCisco, San Jose, CA, USA.
Satyananda KashyapIBM Research, San Jose, CA, USA.ORCID 0000-0002-4624-5690
Nicholas LaneUniversity of Cambridge, Cambridge, UK.
Indranil MallickTata Medical Center, Kolkata, India.
FeTS Consortium
BraTS-2020 Consortium
AI4SafeChole Consortium
Pietro MascagniIHU Strasbourg, Strasbourg, France.ORCID 0000-0001-7288-3023
Virendra MehtaUniversity of Trento, Trento, Italy.ORCID 0000-0001-9447-401X
Cassiano Ferro MoraesWrite Choice, Florianópolis, Brazil.
Vivek NatarajanGoogle, Mountain View, CA, USA.
Nikola NikolovSupermicro, San Jose, CA, USA.
Nicolas PadoyIHU Strasbourg, Strasbourg, France.
Gennady PekhimenkoUniversity of Toronto, Toronto, Ontario, Canada.
Vijay Janapa ReddiHarvard University, Cambridge, MA, USA.
G Anthony ReinaIntel, Santa Clara, CA, USA.
Pablo RibaltaNVIDIA, Santa Clara, CA, USA.
Abhishek SinghMassachusetts Institute of Technology, Cambridge, MA, USA.
Jayaraman J ThiagarajanLawrence Livermore National Laboratory, Livermore, CA, USA.
Jacob AlbrechtSage Bionetworks, Seattle, WA, USA.
Thomas WolfHugging Face, New York, NY, USA.
Geralyn MillerMicrosoft, Redmond, WA, USA.
Huazhu FuA*STAR, Singapore, Singapore.ORCID 0000-0002-9702-5524
Prashant ShahIntel, Santa Clara, CA, USA.
Daguang XuNVIDIA, Santa Clara, CA, USA.
Poonam YadavUniversity of York, York, UK.
David TalbyJohn Snow Labs, Lewes, DE, USA.
Mark M AwadDana-Farber Cancer Institute, Boston, MA, USA.
Jeremy P Howardfast.ai, San Francisco, CA, USA.
Michael RosenthalDana-Farber Cancer Institute, Boston, MA, USA.
Luigi MarchionniWeill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-7336-8071
Massimo LodaDana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-9674-8379
Jason M JohnsonDana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-8677-6237
Spyridon BakasPerelman School of Medicine, Philadelphia, PA, USA.ORCID 0000-0001-8734-6482
Peter MattsonMLCommons, San Francisco, CA, USA.ORCID 0000-0002-5984-238X

Funding

Advancing method benchmarking and data sharing through crowd-sourced competitions in cancer researchU24CA248265 · NCI · SAGE BIONETWORKS · PI BOUTROS, PAUL CHRISTOPHER, VARMA, SUSHEEL · 2020 to 2024
$4.1M
Cancer imaging phenomics software suite: application to brain and breast cancerU24CA189523 · NCI · UNIVERSITY OF PENNSYLVANIA · PI DAVATZIKOS, CHRISTOS, KONTOS, DESPINA · 2015 to 2019
$3.2M
The Federated Tumor Segmentation (FeTS) platform: An intuitive tool facilitating secure multi-institutional collaborationU01CA242871 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BAKAS, SPYRIDON · 2019 to 2021
$1.1M
NCI NIH HHS U01 CA242871NCI NIH HHS U24 CA189523NCI NIH HHS U24 CA248265
6 · The paper itself

Abstract

Medical artificial intelligence (AI) has tremendous potential to advance healthcare by supporting and contributing to the evidence-based practice of medicine, personalizing patient treatment, reducing costs, and improving both healthcare provider and patient experience. Unlocking this potential requires systematic, quantitative evaluation of the performance of medical AI models on large-scale, heterogeneous data capturing diverse patient populations. Here, to meet this need, we introduce MedPerf, an open platform for benchmarking AI models in the medical domain. MedPerf focuses on enabling federated evaluation of AI models, by securely distributing them to different facilities, such as healthcare organizations. This process of bringing the model to the data empowers each facility to assess and verify the performance of AI models in an efficient and human-supervised process, while prioritizing privacy. We describe the current challenges healthcare and AI communities face, the need for an open platform, the design philosophy of MedPerf, its current implementation status and real-world deployment, our roadmap and, importantly, the use of MedPerf with multiple international institutions within cloud-based technology and on-premises scenarios. Finally, we welcome new contributions by researchers and organizations to further strengthen MedPerf as an open benchmarking platform.

Identifiers

PMID38706981
PMCPMC11068064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.